Cargando…

Fine-tuned long-acting interleukin-2 superkine potentiates durable immune responses in mice and non-human primate

BACKGROUND: Recombinant human interleukin-2 (rhIL-2, aldesleukin) is Food and Drug Administration approved for the treatment of metastatic melanoma and renal cell carcinoma and has achieved durable response in a subset of patients. However, its utility as an immunotherapeutic drug is limited by unde...

Descripción completa

Detalles Bibliográficos
Autores principales:	Merchant, Rosemina, Galligan, Carole, Munegowda, Manjunatha Ankathatti, Pearce, L Bruce, Lloyd, Peter, Smith, Paul, Merchant, Fahar, To, Minh D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8772458/ https://www.ncbi.nlm.nih.gov/pubmed/35058325 http://dx.doi.org/10.1136/jitc-2021-003155

Ejemplares similares

Interleukin-2 superkines by computational design
por: Ren, Junming, et al.
Publicado: (2022)

Transient blocking of NK cell function with small molecule inhibitors for helper dependant adenoviral vector-mediated gene delivery
por: Ankathatti Munegowda, Manjunatha, et al.
Publicado: (2015)

Exploiting a natural conformational switch to engineer an Interleukin-2 superkine
por: Levin, Aron M., et al.
Publicado: (2012)

Redirecting cell-type specific cytokine responses with engineered interleukin-4 superkines
por: Junttila, Ilkka S., et al.
Publicado: (2012)

Lung gene therapy—How to capture illumination from the light already present in the tunnel
por: Xia, Emily, et al.
Publicado: (2014)

Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity
por: Chen, Shih-Hsun, et al.
Publicado: (2021)

Antitumor immunity as the basis for durable disease-free treatment-free survival in patients with metastatic urothelial cancer
por: Anker, Jonathan, et al.
Publicado: (2023)

Randomized phase II study of stereotactic body radiotherapy and interleukin-2 versus interleukin-2 in patients with metastatic melanoma
por: Curti, Brendan, et al.
Publicado: (2020)

Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events
por: Siddiqui, Bilal A, et al.
Publicado: (2021)

Sequential ctDNA whole-exome sequencing in advanced lung adenocarcinoma with initial durable tumor response on immune checkpoint inhibitor and late progression
por: Giroux Leprieur, Etienne, et al.
Publicado: (2020)

Oxazaphosphorines combined with immune checkpoint blockers: dose-dependent tuning between immune and cytotoxic effects
por: Delahousse, Julia, et al.
Publicado: (2020)

INBRX-120, a CD8α-targeted detuned IL-2 that selectively expands and activates tumoricidal effector cells for safe and durable in vivo responses
por: Sulzmaier, Florian J, et al.
Publicado: (2023)

IMMU-16. Next-generation CAR T-cells targeting IL13RA2 and secreting IL-15 achieve durable tumour clearance in pre-clinical model of diffuse midline glioma
por: Hotblack, Alastair, et al.
Publicado: (2022)

Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials
por: Ellingsen, Espen Basmo, et al.
Publicado: (2022)

Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events
por: Fa'ak, Faisal, et al.
Publicado: (2023)

Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition
por: Laino, Andressa S, et al.
Publicado: (2020)

Enhanced efficacy and limited systemic cytokine exposure with membrane-anchored interleukin-12 T-cell therapy in murine tumor models
por: Zhang, Ling, et al.
Publicado: (2020)

Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma
por: Katz, Matthew H G, et al.
Publicado: (2023)

Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myeloma
por: Mouhieddine, Tarek H., et al.
Publicado: (2022)

Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies
por: Minnar, Christine M, et al.
Publicado: (2022)

CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation
por: Reyes, Ryan Michael, et al.
Publicado: (2021)

Interleukin-10 induces expression of CD39 on CD8+T cells to potentiate anti-PD1 efficacy in EGFR-mutated non-small cell lung cancer
por: Qiao, Meng, et al.
Publicado: (2022)

Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer
por: Naqash, Abdul Rafeh, et al.
Publicado: (2023)

Efficacy of ruthenium coordination complex–based Rutherrin in a preclinical rat glioblastoma model
por: Munegowda, Manjunatha Akathatti, et al.
Publicado: (2019)

Detection of microsatellite instability-high (MSI-H) by liquid biopsy predicts robust and durable response to immunotherapy in patients with pancreatic cancer
por: Chakrabarti, Sakti, et al.
Publicado: (2022)

Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis
por: Huang, Richard S P, et al.
Publicado: (2023)

Allelic variation of KIR and HLA tunes the cytolytic payload and determines functional hierarchy of NK cell repertoires
por: Philippon, Camille, et al.
Publicado: (2023)

A Nonhuman Primate Scrub Typhus Model: Protective Immune Responses Induced by pKarp47 DNA Vaccination in Cynomolgus Macaques
por: Paris, Daniel H., et al.
Publicado: (2015)

IMMU-01. THE ONCOLYTIC VIRUS DELTA-24-RGD IN COMBINATION WITH AN AGONISTIC CD40 MAB INDUCES A DURABLE AND SYNERGISTIC ANTI-TUMOR IMMUNE EFFECT IN DIPG PRECLINICAL MODELS
por: Labiano, Sara, et al.
Publicado: (2021)

Synergy of a STING agonist and an IL-2 superkine in cancer immunotherapy against MHC I–deficient and MHC I(+) tumors
por: Wolf, Natalie K., et al.
Publicado: (2022)

Interleukin-15 augments NK cell–mediated ADCC of alemtuzumab in patients with CD52(+) T-cell malignancies
por: Miljkovic, Milos D., et al.
Publicado: (2022)

Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy
por: Baker, Megan L, et al.
Publicado: (2022)

Increased tumour dihydroceramide production after Photofrin-PDT alone and improved tumour response after the combination with the ceramide analogue LCL29. Evidence from mouse squamous cell carcinomas
por: Separovic, D, et al.
Publicado: (2009)

Initial dose of oncolytic myxoma virus programs durable antitumor immunity independent of in vivo viral replication
por: Flores, Erica B, et al.
Publicado: (2020)

Novel non-terminal tumor sampling procedure using fine needle aspiration supports immuno-oncology biomarker discovery in preclinical mouse models
por: Sitnikova, Suzanne Isabelle, et al.
Publicado: (2021)

Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma
por: Cebon, Jonathan S, et al.
Publicado: (2020)

CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models
por: Puigdelloses, Montserrat, et al.
Publicado: (2021)

Are non-human primates capable of rhythmic entrainment? Evidence for the gradual audiomotor evolution hypothesis
por: Merchant, Hugo, et al.
Publicado: (2014)

Hypothermia Promotes Interleukin-22 Expression and Fine-Tunes Its Biological Activity
por: Chichelnitskiy, Evgeny, et al.
Publicado: (2017)

An (89)Zr-HDL PET Tracer Monitors Response to a CSF1R Inhibitor
por: Mason, Christian A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_f4rrkb54dtfud5nk2d5j4drlej